16 [145] R. E. Clempus and K. K. Griendling, “Reactive oxygen species signaling in vascular smooth muscle cells,” Cardiovascular Research, vol. 71, no. 2, pp. 216–225, 2006. [146] J. L. Martindale and N. J. Holbrook, “Cellular response to oxidative stress: signaling for suicide and survival,” Journal of Cellular Physiology, vol. 192, no. 1, pp. 1–15, 2002. [147] S. P. Hye, H. L. Seung, D. Park et al., “Sequential activation of phosphatidylinositol 3-kinase, βPix, Rac1, and Nox1 in growth factor-induced production of H2O2 ,” Molecular and Cellular Biology, vol. 24, no. 10, pp. 4384–4394, 2004. [148] P. G. Arthur, M. D. Grounds, and T. Shavlakadze, “Oxidative stress as a therapeutic target during muscle wasting: consid- ering the complex interactions,” Current Opinion in Clinical Nutrition and Metabolic Care, vol. 11, no. 4, pp. 408–416, 2008. [149] J. S. Moylan and M. B. Reid, “Oxidative stress, chronic disease, and muscle wasting,” Muscle and Nerve, vol. 35, no. 4, pp. 411–429, 2007. [150] A. Kokoszko, J. Dabrowski, A. Lewi n´ski, and M. Karbownik- Lewin´ ska, “Protective eﬀects of GH and IGF-I against iron-induced lipid peroxidation in vivo,” Experimental and Toxicologic Pathology, vol. 60, no. 6, pp. 453–458, 2008. [151] S. Y. Yang, M. Hoy, B. Fuller, K. M. Sales, A. M. Seifalian, and M. C. Winslet, “Pretreatment with insulin-like growth factor i protects skeletal muscle cells against oxidative damage via PI3K/Akt and ERK1/2 MAPK pathways,” Laboratory Investigation, vol. 90, no. 3, pp. 391–401, 2010. [152] M. Wallis, “New insulin-like growth factor (IGF)-precursor sequences from mammalian genomes: the molecular evolu- tion of IGFs and associated peptides in primates,” Growth Hormone and IGF Research, vol. 19, no. 1, pp. 12–23, 2009. [153] E. R. Barton, J. Demeo, and H. Lei, “The insulin-like growth factor (IGF)-I E-peptides are required for isoform-speciﬁc gene expression and muscle hypertrophy after local IGF-I production,” Journal of Applied Physiology, vol. 108, no. 5, pp. 1069–1076, 2010. [154] G. Dobrowolny, C. Giacinti, L. Pelosi et al., “Muscle expres- sion of a local Igf-1 isoform protects motor neurons in an ALS mouse model,” Journal of Cell Biology, vol. 168, no. 2, pp. 193–199, 2005. [155] A. Musaro´ , C. Giacinti, G. Borsellino et al., “Stem cell- mediated muscle regeneration is enhanced by local isoform of insulin-like growth factor 1,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 5, pp. 1206–1210, 2004. [156] I. V. Kravchenko, V. A. Furalyov, E. S. Lisitsina, and V. O. Popov, “Stimulation of mechano-growth factor expression by second messengers,” Archives of Biochemistry and Biophysics, vol. 507, no. 2, pp. 323–331, 2011. [157] A. Satoh, C. S. Brace, G. Ben-Josef et al., “SIRT1 promotes the central adaptive response to diet restriction through activation of the dorsomedial and lateral nuclei of the hypothalamus,” Journal of Neuroscience, vol. 30, no. 30, pp. 10220–10232, 2010. [158] U. Berg and P. Bang, “Exercise and circulating insulin-like growth factor I,” Hormone Research, vol. 62, no. 1, pp. 50–58, 2004. [159] E. Eppler, J. Zapf, N. Bailer, U. G. Falkmer, and M. Reinecke, “IGF-I in human breast cancer: low diﬀerentiation stage is associated with decreased IGF-I content,” European Journal of Endocrinology, vol. 146, no. 6, pp. 813–821, 2002. [160] J. Philip Karl, J. A. Alemany, C. Koenig et al., “Diet, body composition, and physical ﬁtness inﬂuences on IGF-I Journal of Signal Transduction bioactivity in women,” Growth Hormone and IGF Research, vol. 19, no. 6, pp. 491–496, 2009. [161] J. Papaconstantinou, “Insulin/IGF-1 and ROS signaling pathway cross-talk in aging and longevity determination,” Molecular and Cellular Endocrinology, vol. 299, no. 1, pp. 89– 100, 2009. [162] N. Bashan, J. Kovsan, I. Kachko, H. Ovadia, and A. Rudich, “Positive and negative regulation of insulin signaling by reactive oxygen and nitrogen species,” Physiological Reviews, vol. 89, no. 1, pp. 27–71, 2009. [163] L. Coderre, K. V. Kandror, G. Vallega, and P. F. Pilch, “Identiﬁcation and characterization of an exercise-sensitive pool of glucose transporters in skeletal muscle,” Journal of Biological Chemistry, vol. 270, no. 46, pp. 27584–27588, 1995. [164] S. Lund, G. D. Holman, O. Schmitz, and O. Pedersen, “Contraction stimulates translocation of glucose transporter GLUT4 in skeletal muscle through a mechanism distinct from that of insulin,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 13, pp. 5817–5821, 1995. [165] A. Katz, S. Broberg, K. Sahlin, and J. Wahren, “Leg glucose uptake during maximal dynamic exercise in humans,” Amer- ican Journal of Physiology, vol. 251, no. 1, part 1, pp. E65–E70, 1986. [166] Y. Higaki, T. Mikami, N. Fujii et al., “Oxidative stress stimu- lates skeletal muscle glucose uptake through a phosphatidyli- nositol 3-kinase-dependent pathway,” American Journal of Physiology—Endocrinology and Metabolism, vol. 294, no. 5, pp. E889–E897, 2008. [167] M. E. Sandstro¨m, S. J. Zhang, J. Bruton et al., “Role of reactive oxygen species in contraction-mediated glucose transport in mouse skeletal muscle,” Journal of Physiology, vol. 575, part 1, pp. 251–262, 2006. [168] D. G. Hardie and K. Sakamoto, “AMPK: a key sensor of fuel and energy status in skeletal muscle,” Physiology, vol. 21, no. 1, pp. 48–60, 2006. [169] T. Hayashi, M. F. Hirshman, E. J. Kurth, W. W. Winder, and L. J. Goodyear, “Evidence for 5’AMP-activated protein kinase mediation of the eﬀect of muscle contraction on glucose transport,” Diabetes, vol. 47, no. 8, pp. 1369–1373, 1998. [170] J. O. Holloszy, “A forty-year memoir of research on the regulation of glucose transport into muscle,” American Journal of Physiology—Endocrinology and Metabolism, vol. 284, no. 3, pp. E453–E467, 2003. [171] E. J. Kurth-Kraczek, M. F. Hirshman, L. J. Goodyear, and W. W. Winder, “5’ AMP-activated protein kinase activation causes GLUT4 translocation in skeletal muscle,” Diabetes, vol. 48, no. 8, pp. 1667–1671, 1999. [172] N. Fujii, N. Jessen, and L. J. Goodyear, “AMP-activated pro- tein kinase and the regulation of glucose transport,” Amer- ican Journal of Physiology—Endocrinology and Metabolism, vol. 291, no. 5, pp. E867–E877, 2006. [173] A. Katz, “Modulation of glucose transport in skeletal muscle by reactive oxygen species,” Journal of Applied Physiology, vol. 102, no. 4, pp. 1671–1676, 2007. [174] E. Latres, A. R. Amini, A. A. Amini et al., “Insulin-like growth factor-1 (IGF-1) inversely regulates atrophy-induced genes via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway,” Journal of Biological Chemistry, vol. 280, no. 4, pp. 2737–2744, 2005. [175] A. M. Solomon and P. M. G. Bouloux, “Modifying muscle mass—The endocrine perspective,” Journal of Endocrinology, vol. 191, no. 2, pp. 349–360, 2006.